UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended ~~March 31,~~September 30, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to __________________

Commission File number 0-54433

MARIMED INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		27-4672745
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		~~(I.R.S. Employer~~ Identification No.)

~~26 Ossipee Road, Suite 201~~10 Oceana Way

~~Newton,~~Norwood, MA ~~02464~~02062

(Address of Principal Executive Offices)

617-795-5140

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

(Check One):

Large Accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [X]
(Do not check if a smaller reporting company)

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of ~~May~~November 14, 2018, ~~183,170,163~~208,398,893 shares of the Issuer’s Common Stock were outstanding.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

MariMed Inc.

Condensed Consolidated Financial Statements

Three and Nine Months Ended ~~March 31,~~September 30, 2018 and 2017

Table of Contents

	Page
Condensed Consolidated Balance Sheets as of ~~March 31,~~September 30, 2018 (Unaudited) and December 31, 2017	3

Condensed Consolidated Statements of Operations for the Three and Nine Months Ended ~~March 31,~~September 30, 2018 and 2017 (Unaudited)	4

Condensed Consolidated Statements of Cash Flows for the ~~Three~~Nine Months Ended ~~March 31,~~September 30, 2018 and 2017 (Unaudited)	5

Notes to Condensed Consolidated Financial Statements (Unaudited)	6

MariMed Inc.

Condensed Consolidated Balance Sheets

March 31, 2018 December 31, 2017
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 409,593 $ 1,290,231
Accounts receivable, net 2,122,044 1,453,484
Deferred rents receivable 724,827 610,789
Due from third parties 1,844,050 1,196,918
Due from related parties 134,781 134,781
Note receivable, current portion 46,879 45,444
Other current assets 376,459 357,019
Total current assets 5,658,633 5,088,666

Property and equipment, net 27,168,997 25,954,931
Note receivable, long-term portion 566,999 578,831
Other assets 543,445 579,587
Total assets $ 33,938,074 $ 32,202,015

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable $ 2,721,103 $ 2,831,658
Accrued expenses 1,445,403 1,405,336
Due to related parties 200,996 400,996
Mortgages payable, current portion 119,668 118,556
Common stock subscriptions 3,236,001 -
Notes payable 9,215,249 10,665,899
Total current liabilities 16,938,420 15,422,445

Mortgages payable, long-term portion 6,026,376 5,532,397
Notes payable - -
Other liabilities 240,013 240,013
Total liabilities 23,204,809 21,194,855

Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued or outstanding at March 31, 2018 and December 31, 2017 - -
Series A preferred stock subscribed but not issued; zero and 500,000 shares at March 31, 2018 and December 31, 2017, respectively - 500
Common stock, $0.001 par value; 500,000,000 shares authorized at March 31, 2018 and December 31, 2017; 179,795,933 and 176,940,331 shares issued at March 31, 2018 and December 31, 2017, respectively; 179,705,933 and 176,850,331 shares outstanding at March 31, 2018 and December 31, 2017, respectively 179,796 176,940
Common stock subscribed but not issued; 1,000,000 shares at March 31, 2018 and December 31, 2017 370,000 370,000
Subscriptions receivable (25,000 ) (25,000 )
Common stock warrants 2,382,726 2,176,379
Treasury stock, at cost; 90,000 shares at March 31, 2018 and December 31, 2017 (45,000 ) (45,000 )
Additional paid-in capital 21,563,178 20,149,591
Accumulated deficit (13,866,883 ) (11,971,740 )
Noncontrolling interests 174,448 175,490
Total stockholders’ equity 10,733,265 11,007,160
Total liabilities and stockholders’ equity $ 33,938,074 $ 32,202,015

	September 30, 2018			December 31, 2017
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	6,027,044		$	1,290,231
Accounts receivable, net		4,019,737			1,453,484
Deferred rents receivable		1,707,697			610,789
Due from third parties		3,122,654			1,196,918
Due from related parties		134,781			134,781
Notereceivable, current portion		49,886			45,444
Other current assets		457,703			357,019
Total current assets		15,519,502			5,088,666

Property and equipment, net		32,768,839			25,954,931
Notesreceivable, less current portion		7,595,302			578,831
Other assets		1,249,856			579,587
Total assets	$	57,133,499		$	32,202,015

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,632,822		$	2,831,658
Accrued expenses		1,460,120			1,405,336
Due to related parties		204,996			400,996
Mortgages payable, current portion		121,199			118,556
Common stock subscriptions		3,860,000			-
Notes payable		4,615,804			10,665,899
Total current liabilities		12,894,941			15,422,445

Mortgages payable, less current portion		7,443,162			5,532,397
Other liabilities		293,768			240,013
Total liabilities		20,631,871			21,194,855

Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at September 30, 2018 and December 31, 2017; no shares issued or outstanding at September 30, 2018 or December 31, 2017		-			-
Series A preferred stock subscribed but not issued; zero and 500,000 shares at September 30, 2018 and December 31, 2017, respectively		-			500
Common stock, $0.001 par value; 500,000,000 shares authorized at September 30, 2018 and December 31, 2017; 203,466,907 and 176,940,331 shares issued at September 30, 2018 and December 31, 2017, respectively; 203,121,380 and 176,850,331 shares outstanding at September 30, 2018 and December 31, 2017, respectively		203,467			176,940
Common stock subscribed but not issued; zero and 1,000,000 shares at September 30, 2018 and December 31, 2017		-			370,000
Subscriptions receivable		-			(25,000	)
Common stock warrants		16,413,608			2,176,379
Treasury stock, at cost; 345,528 and 90,000 shares at September 30, 2018 and December 31, 2017, respectively		(643,000	)		(45,000	)
Additional paid-in capital		51,052,902			20,149,591
Accumulated deficit		(30,417,269	)		(11,971,740	)
Noncontrolling interests		(108,080	)		175,490
Total stockholders’ equity		36,501,628			11,007,160
Total liabilities and stockholders’ equity	$	57,133,499		$	32,202,015

See accompanying notes to condensed consolidated financial statements.

MariMed Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended March 31,						Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017			2018			2017

Revenues	$	2,082,950		$	1,150,719		$	3,391,582		$	1,715,697		$	8,411,858		$	4,487,473

Cost of revenues, including depreciation		888,869			471,068			1,521,783			548,181			3,324,009			1,488,542

Gross profit		1,194,081			679,651			1,869,799			1,167,516			5,087,849			2,998,931

Operating expenses:
Personnel		184,671			167,862			352,257			269,795			821,815			574,481
Marketing and promotion		51,761			69,469			37,202			29,286			166,906			144,020
General and administrative		706,483			213,768			619,419			581,391			2,140,816			1,163,718
Total operating expenses		942,915			451,099			1,008,878			880,472			3,129,535			1,882,218

Operating income		251,166			228,552			860,921			287,044			1,958,314			1,116,713

Non-operating expenses:
Interest expense, net		296,427			81,592			454,847			89,934			1,018,460			267,840
Equity compensation		572,807			19,295
Amortization of stock option and warrant issuances								8,109,661			274,224			14,973,270			293,519
Loss on debt settlements		1,213,841			18,278			2,407,671			463,855			4,184,631			482,133
Other								-			(226,940	)		3,600			(226,940	)
Total non-operating expenses		2,083,075			119,165			10,972,179			601,073			20,179,961			816,552

Net income (loss)	$	(1,831,909	)	$	109,387			(10,111,258	)		(314,029	)		(18,221,647	)		300,161

Net income (loss) to noncontrolling interests	$	63,233		$	141,626
Net income (loss) attributable to noncontrolling interests								91,362			78,421			223,882			177,852
Net income (loss) attributable to MariMed Inc.	$	(1,895,142	)	$	(33,240	)	$	(10,202,620	)	$	(392,450	)	$	(18,445,529	)	$	122,309

Net income (loss) per share	$	(0.011	)	$	(0.001	)	$	(0.052	)	$	(0.002	)	$	(0.099	)	$	0.001
Weighted average common shares outstanding		178,914,829			64,208,389			196,415,503			163,737,564			186,952,362			97,982,499

See accompanying notes to condensed consolidated financial statements.

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended March 31,						Nine Months Ended September 30,
	2018			2017			2018			2017
Cash flows from operating activities:
Net income (loss) attributable to MariMed Inc.	$	(1,895,142	)	$	(32,240	)	$	(18,445,529	)	$	122,309
Net income (loss) attributable to noncontrolling interests		63,233			141,626			223,882			177,852
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation		80,791			69,827			445,504			263,624
Equity compensation		572,807			19,295
Amortization of stock option and warrant issuances								15,026,148			293,519
Common stock issued for services								3,640,621			38,965
Loss on preferred stock conversions								34,044			-
Loss on debt settlements		1,213,841			18,278			3,210,472			482,133
Changes in operating assets and liabilities:
Accounts receivable, net		(668,561	)		26,223			(2,566,254	)		(793,081	)
Deferred rents receivable		(114,038	)		219,126			(1,096,908	)		(71,887	)
Due from third parties		(647,131	)		(22,486	)		(1,925,735	)		(467,583	)
Due from related parties		-			(391,886	)		-			52,727
Other current assets		(19,440	)		(319,451	)		(100,684	)		(66,422	)
Other assets		36,142			-			29,731			(169,990	)
Accounts payable		(110,555	)		297,535			(198,836	)		3,069,948
Accrued expenses		616,213			153,179			129,689			(22,495	)
Due to related parties		(200,000	)		626			(196,000	)		(53,342	)
Deferred revenue								-			(226,950	)
Other liabilities		-			(26,034	)		53,755			500
Net cash provided by (used in) operating activities		(1,071,840	)		134,323			(1,736,100	)		2,629,827

Cash flows from investing activities:
Purchase of property and equipment		(1,294,858	)		(1,806,655	)		(7,259,413	)		(11,502,688	)
Investment in debentures and notes								(7,050,000	)		-
Investment in Sprout								(100,000	)		-
Interest on notes receivable		10,398			9,641			29,087			29,625
Net cash used in investing activities		(1,284,460	)		(1,797,014	)		(14,380,326	)		(11,473,063	)

Cash flows from financing activities:
Proceeds from subscribed common stock		875,000			1,300,000
Proceeds from subscribed preferred stock								-			200,000
Issuance of common stock		600,000			-			16,896,000			5,150,000
Issuance of interest in subsidiary		-			150,000
Issuance (repayment) of promissory notes		(500,000	)		400,000
Issuance (repayments) of promissory notes, net								2,300,000			3,650,000
Proceeds from (payments of) mortgages payable, net		495,091			(28,515	)		1,913,408			(80,622	)
Exercise of stock options		39,000			-			39,000			7,500
Exercise of warrants		30,846			-			212,284			-
Distributions		(64,275	)		(87,868	)		(507,453	)		-
Net cash provided by financing activities		1,475,662			1,733,617			20,853,239			8,926,878

Net change to cash and cash equivalents		(880,638	)		70,926			4,736,813			83,642
Cash and cash equivalents at beginning of period		1,290,231			569,356			1,290,231			569,356
Cash and cash equivalents at end of period	$	409,593		$	640,282		$	6,027,044		$	652,998

*Supplemental disclosure of cash flow information:*
Cash paid for interest	$	291,912		$	71,853		$	931,195		$	418,738
Cash paid for taxes	$	12,596		$	-		$	12,021		$	8,138

*Non-cash activities:*
Equity issued to settle debt	$	-		$	38,965		$	8,425,000		$	2,050,000
Equity issued for acquisitions							$	600,000		$	370,000

See accompanying notes to condensed consolidated financial ~~statements~~statements.

MariMed Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

MariMed Inc., (the “Company”), a Delaware corporation, ~~is a professional management company in the emerging medical cannabis industry. The Company advises its clients in securing cannabis licenses, and in turn,~~ develops and manages ~~on behalf of its clients,~~ state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products. Such facilities, located in multiple states, are leased to the Company’s clients in the emerging cannabis industry. Along with ~~this~~ operational oversight, the Company provides its clients with legal, accounting, human resources, business development, and other corporate and administrative services.

The Company also provides professional consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states—two in Delaware, two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, the Company has developed over 300,000 square feet of seed-to-sale cannabis facilities across these five states.

In addition, the Company licenses ~~a custom brand of~~precision-dosed, cannabis-infused products to treat specific medical conditions or to achieve a certain result. These products are licensed under the brand ~~name~~names Kalm Fusion™ and Nature’s Heritage™, both of which ~~are precision-dosed and designed for specific medical conditions and related symptoms. In October 2017,~~were developed by the Company, ~~expanded its product line with~~and Betty’s Eddies™, acquired in October 2017. The Company also has exclusive sublicensing rights in certain states to distribute vaporizer pens developed by Lucid Mood™, as well as the ~~acquisition of the Betty’s Eddies™ brand of cannabis-infused fruit chews,~~

clinically-tested medicinal cannabis strains developed in Israel by Tikun Olam™.

The Company’s stock is quoted on the OTCQB market under the ticker symbol MRMD.

The Company was originally incorporated in January 2011 under the name Worlds Online Inc., using the ticker symbol WORX. In early 2017, the Company name and ticker were changed to its current name and ticker. Since inception, the Company ~~has~~had operated an online portal that offers multi-user virtual environments to users. This segment of the business has had insignificant operations since early 2014.

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC, a company operating in ~~exchange for (i) an aggregate amount~~the cannabis industry. The purchase price consisted of ~~the Company’s~~Company common stock, ~~equal to 50% of the Company’s outstanding shares on the closing date, (ii)~~ options to purchase ~~three million shares of the Company’s~~additional Company common stock, ~~exercisable over five years with exercise prices ranging from $0.15 to $0.35,~~ and ~~(iii)~~ a ~~49% ownership~~minority interest in MariMed Advisors ~~Inc..~~Inc. This transaction, ~~which~~further disclosed in Note 3, was accounted for as a purchase acquisition where the Company was both the legal and accounting ~~acquirer,~~acquirer. In June 2017, the minority interest in MariMed Advisors Inc. was merged into the Company.

In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry. This acquisition is further disclosed in Note ~~8 below.~~3.

In July 2018, the Company contracted to acquire an entity that holds a license for the cultivation of cannabis into medical marijuana products in the state of Pennsylvania, as further disclosed in Note 3.

In ~~June 2017,~~October 2018, the Company entered into a purchase agreement to acquire its two cannabis-licensed clients currently operating medical marijuana dispensaries in the state of Illinois. The execution of this agreement occurred subsequent to the quarter end as further disclosed in Note 14.

In October 2018, the Company’s cannabis-licensed client with cultivating and dispensing operations in Massachusetts filed a plan of entity conversion with the state to convert from a non-profit entity to a for-profit corporation. Upon approval of the conversion plan by the state, the for-profit corporation shall be wholly-owned by the Company as further disclosed in Note 14.

In October 2018, the Company acquired BSC Group LLC, a multidisciplinary advisory firm that provides operational, marketing, and licensing management services to companies within the ~~remaining 49% interest in MMA in exchange for 75 million shares of common stock.~~

cannabis industry.

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s audited annual financial statements and accompanying notes for the year ended December 31, 2017.

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its ~~subsidiaries, all of which are majority-owned.~~majority-owned subsidiaries. Intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.

Cash Equivalents

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.

Revenue Recognition

The Company’s main sources of revenue are comprised of: leasing ~~contracts with~~of its ~~medical~~developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support ~~of client~~to its clients’ operations; consulting services to companies operating in the medical and legal ~~and medical~~recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing ~~revenues from the sale~~ of ~~its~~ branded cannabis products.

On January 1, 2018, the Company adopted the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606,Revenue from Contract with Customers,as amended by subsequently issued Accounting Standards Updates. This revenue standard requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. The ~~Company recognizes revenue when all~~adoption of this standard did not have a significant impact on the ~~following criteria are met: evidence of an arrangement exists such as a signed contract, delivery~~Company’s consolidated operating results, and accordingly no restatement has ~~occurred/services have~~ been ~~performed, the price is fixed or determinable, and collectability is reasonably assured.~~made to prior period reported amounts.

Research and Development Costs

Research and development costs are charged to operations as incurred.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset’s carrying amount over its estimated fair value.

Impairment analyses are based on management’s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.

For the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.

Impairment of ~~Long Lived~~Long-Lived Assets

The Company evaluates the recoverability of its fixed assets and other assets in accordance with ~~the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”)~~ASC 360-10-15,Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.

Fair Value of Financial Instruments

The Company follows the provisions of ASC 820,Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825,Financial Instruments,for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3	Pricing inputs that are generally observable inputs and not corroborated by market data.

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.

Extinguishment of Liabilities

The Company accounts for extinguishment of liabilities in accordance with ASC 405-20,Extinguishments of Liabilities.When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.

Stock-Based Compensation

The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718,Compensation—Stock Compensation,which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740,Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017.

Related Party Transactions

The Company follows ASC 850,Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.

Comprehensive Income

The Company reports comprehensive income and its components following guidance set forth by ASC 220,Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.

Earnings Per Share

Earnings per common share is computed pursuant to ASC 260,Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.

As of ~~March 31,~~September 30, 2018 and 2017, there were ~~10,005,697~~15,497,823 and ~~10,475,000,~~6,748,898, respectively, of potentially dilutive securities in the form of options and warrants. Also as of ~~March 31,~~September 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and ~~$550,000~~$350,000 and ~~$3,125,000,~~$1,075,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. ~~All~~For the nine months ended September 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share ~~calculation. For that reason, the~~calculation, resulting in calculations of basic and fully diluted net income per share that were identical for ~~the three months ended March 31, 2018 and 2017.~~this period. These securities may dilute earnings per share in the future.

Commitments and Contingencies

The Company follows ASC 450,Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

Risk and Uncertainties

The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.

Noncontrolling Interests

Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.

Off Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements.

Recent Accounting Pronouncements

In ~~November~~February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02,Leases (Topic 842), which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2019 and the Company is currently evaluating the impact of adoption, which will be determined by the Company’s lease portfolio at the time of implementation.

In November 2016, the FASB issued ASU No. 2016-18,Statement of Cash Flows (Topic 230): Restricted Cash, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.

In ~~February 2016,~~January 2017, the FASB issued ASU ~~No. 2016-02,~~2017-04,~~Leases~~Intangibles - Goodwill and Other (Topic ~~842)~~350), which ~~modifies accounting for lessees~~simplifies goodwill impairment testing by requiring that such periodic testing be performed by comparing the ~~recording~~fair value of ~~lease assets~~a reporting unit with its carrying amount and ~~liabilities~~recognizing an impairment charge for ~~operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and~~ the amount by which the carrying amount exceeds the reporting unit’s fair value. The Company is currently evaluating the impact of ~~adoption,~~this ASU on its consolidated financial statements and related disclosures, which ~~will be determined by the Company’s lease portfolio at the time of implementation.~~is effective for fiscal years, including interim periods, beginning after December 15, 2019.

In ~~2014 and subsequently in 2016,~~June 2018, the FASB issued ~~new standards on~~ASU 2018-07,Compensation - Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting,which is part of the ~~recognition~~FASB’s simplification initiative to maintain or improve the usefulness of ~~revenue. While~~ the ~~new standards amend~~information provided to the ~~current standards, they are not expected to have a material impact on the amount~~users of financial statements while reducing cost and ~~timing of revenue recognized~~complexity in financial reporting. This update provides consistency in the ~~Company’s consolidated~~accounting for share-based payments to nonemployees with that of employees. This update is effective for interim and annual reporting periods beginning after December 15, 2018, and the Company is currently evaluating its financial ~~statements when the new standards are adopted in 2019.~~statement impact.

In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

NOTE 3 – ACQUISITIONS

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC from its ownership group which included the current CEO and CFO of the Company (the “Sigal Ownership Group”). The purchase price received by the Sigal Ownership Group was comprised of (i) 31,954,236 shares of common stock valued at approximately $5,913.000, representing 50% of the Company’s outstanding shares on the closing date, (ii) options to purchase three million shares of the Company’s common stock, exercisable over five years with exercise prices ranging from $0.15 to $0.35, and valued at approximately $570,000, and (iii) a 49% ownership interest in MariMed Advisors Inc. The excess of purchase price over the book value of the acquired entity was recorded as goodwill, which was subsequently impaired in full and written down to zero.

In June 2017, the remaining 49% interest of MariMed Advisors Inc. was merged into the Company in exchange for an aggregate 75 million shares of common stock to the Sigal Ownership Group.

In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, know-how, and other certain assets of the Betty’s Eddies™ brand of cannabis-infused fruit chews. The purchase price was $140,000 plus subscriptions on 1,000,000 shares of the Company’s common stock. The shares of common stock associated with these subscriptions were subsequently issued in June 2018. In addition, the selling company shall receive royalties based on a percentage of the Company’s sales of the Betty’s Eddies™ product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met. For the nine months ended September 30, 2018, such royalties approximated $14,000, of which $5,000 were paid and $9,000 accrued at September 30, 2018.

After applying the total purchase price, which consisted of the cash paid plus the fair value of the subscribed common stock on the date of the transaction, to the assessed fair values of the assets purchased, the transaction gave rise to goodwill of approximately $333,000. At September 30, 2018 and December 31, 2017, the Company reviewed the goodwill for impairment and determined that, based on the present value of future cash flows of the acquired assets, there was no impairment. The goodwill was included inOther Assets in the Company’s financial statements.

In May 2018, the Company issued $600,000 of subscriptions on common stock in exchange for 100% of the ownership interests of iRollie LLC. The Company acquired, among other assets and liabilities, iRollie’s entire product line, service offerings, clients, and intellectual property, and hired its two co-founders. After applying the purchase price to the fair value of the assets acquired and liabilities assumed, the Company recorded goodwill of approximately$119,000. At September 30, 2018, the Company determined that the goodwill had not been impaired, which was included inOther Assetsin the Company’s financial statements.

In July 2018, the Company entered into a purchase agreement to acquire 100% of the ownership interests of AgriMed Industries of PA LLC, an entity that holds a license from the state of Pennsylvania for the cultivation of cannabis (“AgriMed”). AgriMed presently develops cannabis products that are wholesaled to medical marijuana dispensaries within the state. The purchase price is comprised of $8,000,000, a portion of which may be in the form of the Company’s common stock at the seller’s option, and the assumption of certain liabilities of AgriMed not to exceed $700,000. As required by state law, and in order to effectuate the transaction, the parties have applied for legislative approval of the change in AgriMed’s ownership with respect to the Company’s acquisition. The Company expects to receive written evidence thereof prior to the end of the 2018 fiscal year, at which time the Company will consolidate the operations of AgriMed in accordance with GAAP.

NOTE 4 – INVESTMENTS

In August 2018, the Company invested $100,000, of a total contracted cash investment of $500,000, and agreed to issue 378,259 shares of common stock in exchange for 23% ownership in an entity that provides a customer relationship management and marketing platform specifically designed for companies in the cannabis industry whose product is branded Sprout. The investment balance at September 30, 2018 of $100,000 is included inOther Assetson the Company’s balance sheet. After the total cash and stock investment is made, which is expected to occur prior to the end of the 2018 fiscal year, the investment shall be accounted for under the equity method.

The Company shall assist in the ongoing development and design of Sprout, and in marketing Sprout to companies within the cannabis industry. The Company shall earn a percentage share of the revenue from sales of Sprout (i) to its current clients, and (ii) made by the Company to third parties. As of September 30, 2018, no such share of revenue was earned.

In August 2018, the Company invested $250,000 to obtain the exclusive worldwide license to sublicense, use, develop, promote, sell or otherwise commercialize in any way a technology to produce and distribute cannabis products with exceedingly precise dosing at increased production economies (“the Vitiprints license”). The amount invested was expensed and is included inCost of Revenues, Including Depreciation within the financial statements.

Under this licensing agreement, the Company shall pay a royalty to Vitiprints equal to 10% of the net revenue, as defined, earned by the Company from sales of the Vitiprints license, with a minimum royalty of $250,000 during the initial five-year term, and $250,000 for each five-year renewal term, if renewed. As of September 30, 2018, no such net revenue was earned.

NOTE 5 – NOTES RECEIVABLE

In September 2018, the Company purchased $6.75M of subordinated secured convertible debentures (the “GC Debentures”) of GenCanna Global, Inc., a producer and distributor of agricultural hemp, cannabidiol (CBD) formulations, hemp genetics, and hemp products (“GenCanna”). The GC Debentures bear interest at a compounded rate of 9% per annum and mature three years from issuance.

The GC Debentures are convertible into the common stock of GenCanna, at the Company’s option, (i) upon the occurrence of a Liquidity Event, as defined in the GC Debentures, or (ii) after December 31, 2018, upon ten days prior written notice to GenCanna. The conversion price is equal to the lesser of a 20% discount to the price of the Liquidity Event, or the price based on a defined post-money valuation of GenCanna. If a Liquidity Event does not occur on or before June 30, 2020, the Company shall have the option to be redeemed in cash for the principal amount of the GC Debenture plus all accrued and unpaid interest thereon.

Subsequent to September 30, 2018, the Company entered into a subscription agreement with GenCanna to purchase an aggregate of $30 million of GC Debentures, as disclosed in Note 14 below.

During the nine months ended September 30, 2018, the Company loaned an aggregate of $300,000 to two third-party companies in the cannabis industry. The loans plus accrued interest at the rate of 8% per annum are expected to be repaid by the end of fiscal year 2019.

The Company loaned approximately $700,000 to its Delaware cannabis-licensee client during the period of October 2015 to April 2016. In May 2016, this client issued a 10-year promissory note, as amended, to the Company bearing interest at a compounded rate of 12.5% per annum. The monthly payments of approximately $10,100 will continue through April 2026, at which time the note will be fully paid down. At September 30, 2018 and December 31, 2017, the current portion of this note comprised theNote Receivable, Current Portion amounts on the balance sheet, and the long-term portion of approximately $541,000 and $579,000, respectively, along with the aforementioned notes receivable in this Note 5, were reflected in the captionNotes Receivable, Less Current Portion.

NOTE 36 – PROPERTY AND EQUIPMENT

Property and equipment are shown net of accumulated depreciation and are primarily comprised of the following: land; buildings; building and tenant improvements; furniture and fixtures; and machinery and equipment.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017, additions to property and equipment were approximately ~~$1.3~~$7.3 million and ~~$1.8~~$11.5 million, respectively.

Depreciation expense for the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017 was approximately ~~$81,000~~$446,000 and ~~$70,000,~~$264,000, respectively. At ~~March 31,~~September 30, 2018 and December 31, 2017, accumulated depreciation approximated ~~$1,580,000~~$1,944,000 and $1,499,000, respectively.

NOTE 47 – DEBT

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, the Company received additional capital of approximately ~~$525,000~~$1,998,000 from the existing mortgage on ~~its~~the cannabis cultivation and processing facility it is currently developing in ~~development in~~the state of Massachusetts.

~~During the three months ended March 31, 2017,~~In September 2018, the Company raised ~~$400,000~~$3,000,000 from the issuance of a secured promissory note bearing interest at the rate of 10% per annum, with interest payable monthly. The note is due and payable in September 2019, however the Company may elect to prepay the note in whole or part at any time after December 17, 2018 without premium or penalty. In addition, the Company issued three-year warrants to lender designees to purchase 750,000 shares of common stock at an exercise price of $1.80 per share.

During the nine months ended September 30, 2017, the Company raised $3,650,000 from the issuance of promissory notes, each with an interest rate of 10% per annum and aan initial term of 6 ~~months. No~~months with the ability to extend.

In August 2018, the holder of previously issued promissory notes ~~were issued during the three months ended March 31, 2018.~~

~~During the three months ended March 31, 2018, the Company repaid $500,000~~with principal balances of ~~promissory notes, and~~$3,250,000 converted ~~$975,000 of~~such promissory notes into subscriptions on ~~1,346,153~~1,231,060 shares of common stock ~~as further disclosed~~at a conversion price equal to the market value of the stock on the conversion date of $2.64 per share.

During the nine months ended September 30, 2018, holders of previously issued promissory notes with principal balances of $5,175,000 and accrued and unpaid interest of approximately $93,000 converted such promissory notes into 4,018,534 shares of common stock at conversion prices ranging from $0.65 to $1.75 per share. The conversions resulted in ~~Note 5 below.~~the recording of non-cash losses of approximately $3,210,000 in the aggregate, based on the market value of the common stock on the conversion dates.

During the nine months ended September 30, 2017, the Company issued 4,385,823 shares of common stock to retire promissory notes with principal balances of $2,050,000 plus approximately $262,000 of accrued and unpaid interest. The Company recorded a non-cash loss of approximately $451,000 based on the fair value of the common stock on the transaction date. These former noteholders also received warrants to purchase 863,898 shares of common stock. The fair value of these warrants recorded by the Company on the grant date approximated $257,000.

During the nine months ended September 30, 2018, the Company repaid $700,000 of promissory notes. No repayments ~~or conversions of~~ debt occurred during the same period in 2017.

NOTE 58 – EQUITY

Preferred Stock

In January 2017, the Company increased the number of authorized shares of preferred stock from 5 million to 50 million shares.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2017, the Company issued subscriptions on 200,000 shares of Series A convertible preferred stock at $1.00 per share. ~~This~~No subscriptions were issued during the same period in 2018.

Series A convertible preferred stock accrues an annual dividend of six percent until ~~conversion.~~

~~The Series A convertible preferred stock~~conversion, and is convertible, along with any accrued dividends, into common stock at a twenty-five percent discount to the selling price of the common stock in a qualified offering, as defined in the subscription agreement. In addition, the Company shall have the ability to force the conversion of preferred stock at such time the Company has a market capitalization in excess of $50 million for ten consecutive trading days. In such event, the conversion price shall be a 25% discount to the average closing price of the Company’s common stock over the ten trading days prior to the Company’s notice of its intent to convert.

~~During the three months ended March 31,~~In January 2018, all 500,000 shares of subscribed Series A convertible preferred stock were converted into 970,989 shares of common stock at a conversion price of ~~$0.55.~~$0.55 per share. The Company recorded a non-cash loss on conversion of approximately $34,000 based on the market value of the common stock on the conversion date. No shares were converted during the same period in 2017.

Common Stock

In January 2017, the Company increased the number of authorized shares of common stock from 100 million to 500 million shares.

In June 2017, the Company issued 75 million shares of common stock to acquire the remaining 49% interest in its subsidiary MariMed Advisors Inc.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, the Company sold ~~1,200,000~~14,189,738 shares of common stock at ~~a price of~~prices ranging from $0.50 to $2.70 per share, resulting in total proceeds of ~~$600,000.~~$16,896,000. During the same period in 2017, the Company sold ~~6,467,778~~22,178,888 shares of common stock at prices of $0.18 and $0.25 per share, resulting in total proceeds of ~~$1,300,000.~~

$5,150,000.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017, the Company issued ~~170,000~~3,350,934 and ~~169,487~~531,597 shares ~~respectively,~~ of common stock, respectively for services rendered by ~~the former CFO of the Company. Based on the market value of the common stock on the dates of the two issuances, the~~third parties. The Company recorded non-cash losses of approximately ~~$112,000~~$1,015,000 in 2018 and ~~$18,000~~$31,000 in ~~2017.~~

~~During the three months ended March 31, 2018, the Company issued 125,000 shares of common stock to settle an outstanding obligation. The Company recorded a non-cash loss of approximately $91,000~~2017, based on the market value of the common stock on the issuance ~~date.~~dates.

Subscribed Common Stock

In September 2017, options to purchase 4.8 million shares of common stock were exercised at prices ranging from $0.010 to $0.025, as discussed in Note 9 below. Of this amount, 4.5 million shares were exercised by the former CEO of the Company, who is currently a board member, and 300,000 shares were exercised by the former CFO of the Company. The shares of common stock were issued to these individuals in October 2017.

~~Common Stock Subscriptions~~

~~During the three months ended March 31, 2018,~~ In October 2017, the Company issued subscriptions on ~~1,319,432~~1,000,000 shares of common stock as part of the purchase price of the Betty’s Eddies™ acquired assets, as disclosed in Note 3. These subscriptions, valued at ~~prices of $0.65 and $0.95 per share, resulting in total proceeds of $875,000. No subscriptions on common stock were issued during the same period in 2017.~~

~~In February 2018, two promissory notes totaling $975,000 were converted into subscriptions on 1,346,153 shares of common stock. Based~~$370,000 based on the ~~market value~~price of the common stock on the ~~conversion dates,~~issuance date, were classified underCommon Stock Subscribed But Not Issued within the ~~Company recorded a non-cash loss on~~equity section of the Company’s balance sheet at December 31, 2017.The shares of common stock associated with these ~~conversions of approximately $552,000.~~subscriptions were issued in June 2018.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, the Company issued (i) subscriptions on ~~738,462~~264,317 shares of common stock to ~~settle an outstanding obligation. The Company recorded a non-cash loss of approximately $459,000~~acquire iRollie LLC, valued at $600,000 based on the ~~market value~~price of the common stock on the ~~settlement date.~~

Allissuance date, as disclosed in Note 3, (ii) subscriptions on 2,894 shares of common stock, equivalent to an aggregate amount of $10,000, for the payment of rent for the month of September 2018 for a leased property in Massachusetts, and (iii) subscriptions on 1,231,060 shares of common stock to convert previously issued promissory notes with principal balances of $3,250,000 at a conversion price of $2.64 per share, as disclosed in Note 7. These subscriptions on common stock ~~referred to above are reflected~~were classified under ~~the caption~~Common Stock Subscriptionswithin the current liabilities section of the Company’s balance sheet.

Membership Interests

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, an individual member of Mari Holdings MD LLC, a majority owned subsidiary of the Company, exchanged his membership interest in such subsidiary for 222,222 shares of the Company’s common stock. During the nine months ended September 30, 2017, the Company issued 1,667 Class A membership units of ~~Mari Holdings MD LLC, a majority-owned subsidiary,~~Mari-MD for ~~$150,000. These units represented~~$150,000, representing 0.33% ownership of this subsidiary on the transaction date.

In September 2018, a receivable balance of $25,000, related to previously issued membership interests in a majority-owned subsidiary, was settled by way of the membership interest holder providing consulting services to the Company at ~~March 31, 2017. No membership units were issued during~~a value equivalent to the ~~three months ended March 31, 2018.~~

outstanding balance.

NOTE 69 – STOCK OPTIONS

~~During the three months ended March 31,~~

In January 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77 ~~vesting over a six-month period,~~ and expiring between December 2020 and December 2022. The fair value of these options on grant date of approximately $458,000 ~~shall be recorded as non-cash compensation expense~~was amortized over the six-month vesting ~~periods, with approximately $366,000 incurred~~period during the ~~three~~nine months ended ~~March 31,~~September 30, 2018.

~~In February~~

During the nine months ended September 30, 2018, the ~~former CFO~~Company granted options to purchase 850,000 shares of common stock to newly-hired employees at exercise prices ranging from $0.90 to $2.65 per share, expiring five years from the grant date. As of September 30, 2018, the Company recorded approximately $181,000 of the total fair value of these grants of approximately $2,083,000, which is being amortized over the five-year vesting periods.

During the nine months ended September 30, 2017, the Company ~~exercised~~granted options to purchase 300,000 shares of common stock to newly-hired employees at anexercise prices ranging from $0.26 to $0.55, and expiring in September 2020, March 2021, and April 2021. The fair value of these options on the grant date approximated $73,000, of which approximately $46,000 is being amortized over the respective vesting periods, and approximately $27,000 was forfeited by the option holder.

During the nine months ended September 30, 2018, options to purchase 700,000 shares of common stock were exercised at exercise prices ranging from $0.08 to $0.63 per share by a current board member (400,000 shares) and the former CFO of the Company (300,000 shares). During the same period ended September 30, 2017, options to purchase 4.8 million shares of common stock were exercised at prices ranging from $0.010 to $0.025. As discussed in Note 8 above, of the total exercised shares during this period, 4.5 million shares were exercised by the former CEO of the Company, who is currently a board member, and 300,000 shares were exercised by the former CFO of the Company. The former CEO’s exercise price of ~~$0.13.~~$0.01 per share, or $45,000 in the aggregate, was paid with the surrender of 90,000 shares of common stock. These surrendered shares were classified as treasury stock.

Options to purchase 300,000 shares of common stock were forfeited during the nine-month period ended September 30, 2018. No options were ~~exercised~~forfeited during the same period in ~~2017~~2017.

Stock options outstanding and exercisable as of ~~March 31,~~September 30, 2018 were:

Exercise Price Shares Under Option Remaining
per Share Outstanding Exercisable Life in Years
$ 0.080 250,000 250,000 0.83
$ 0.080 200,000 200,000 1.72
$ 0.130 300,000 300,000 2.25
$ 0.140 750,000 750,000 2.76
$ 0.150 1,000,000 1,000,000 1.50
$ 0.250 1,000,000 1,000,000 1.50
$ 0.260 50,000 50,000 3.01
$ 0.330 50,000 25,000 2.94
$ 0.350 1,000,000 1,000,000 1.50
$ 0.450 250,000 - 3.51
$ 0.550 100,000 - 2.50
$ 0.630 400,000 400,000 3.76
$ 0.770 300,000 - 4.76
5,650,000 4,975,000

Exercise Price		Shares Under Option				Remaining
per Share		Outstanding		Exercisable		Life in Years
$	0.080		250,000		250,000		0.33
$	0.080		100,000		100,000		1.22
$	0.130		200,000		200,000		1.75
$	0.140		650,000		650,000		2.25
$	0.150		1,000,000		1,000,000		0.99
$	0.250		1,000,000		1,000,000		0.99
$	0.260		50,000		50,000		2.51
$	0.330		50,000		25,000		2.44
$	0.350		1,000,000		1,000,000		0.99
$	0.450		250,000		125,000		3.01
$	0.550		100,000		100,000		1.99
$	0.630		300,000		300,000		3.25
$	0.770		300,000		-		4.25
$	0.900		200,000		-		4.62
$	0.950		50,000		-		4.25
$	2.320		300,000		-		4.95
$	2.500		100,000		-		4.91
$	2.650		200,000		-		4.99
			6,100,000		4,800,000

NOTE 710 – WARRANTS

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018 and 2017, the Company issued warrants to purchase ~~200,000~~7,209,974 and ~~100,000~~1,189,280 shares of common stock, respectively, at exercise prices ~~of $1.15 and $0.50~~ranging from $0.30 to $4.30 per share in 2018 and ~~expiring~~$0.40 to $0.62 per share in ~~February 2021 and March 2020, respectively.~~2017. These warrants generally expire three or five years from issuance date. The Company recorded ~~non-cash compensation expense of approximately $206,000 in 2018 and $19,000 in 2017 representing~~ the ~~estimated~~ fair value of these ~~instruments~~warrants, based on the market value of the Company’s common stock on the issuance ~~dates.~~ dates, of approximately $14,237,000 in 2018 and $344,000 in 2017.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, warrants to purchase ~~89,614~~2,057,462 shares of common stock were exercised, at exercise prices ~~of $0.20 and $0.40.~~ranging from $0.10 to $0.50 per share. No warrants were exercised during the same period in 2017.

At ~~March 31,~~September 30, 2018, ~~and 2017,~~ warrants to purchase ~~4,355,697 and 1,225,000~~9,397,823 shares of common stock were outstanding ~~respectively,~~ at exercise prices ranging ~~between $0.10 and $1.15.~~from $0.12 to $4.30 per share.

NOTE 811 – RELATED PARTY TRANSACTIONS

As disclosed in Note 13 above, ~~in May 2014,~~ the ~~Company acquired Sigal Consulting LLC from its ownership group which included the~~current CEO and CFO of the Company ~~(the “Sigal Ownership Group”). The purchase price received by~~are part of the Sigal Ownership Group from whom Sigal Consulting LLC was ~~comprised of (i) 31,954,236 shares of common stock valued at approximately $5,913.000, representing 50%~~acquired in May 2014. The 49% ownership in the Company’s subsidiary, MariMed Advisors Inc., which the Sigal Ownership Group acquired as part of the ~~Company’s outstanding shares on~~purchase price, was acquired by the ~~closing date, (ii) options to purchase three~~Company from the Sigal Ownership Group in June 2017 in exchange for 75 million shares of the Company’s common stock valued at approximately $570,000, and (iii) a 49% ownership interest in the Company’s subsidiary MariMed Advisors, Inc. The excess of purchase price over the book value of the acquired entity was recorded as goodwill, which was subsequently impaired in full and written down to zero.

stock.

In ~~June~~October 2017, the Company acquired the ~~remaining 49% interest~~intellectual property, formulations, recipes, proprietary equipment, and know-how of ~~MariMed Advisors Inc.~~the Betty’s Eddies™ brand of cannabis-infused products, as disclosed in Note 3, from a company that is minority-owned by the ~~Sigal Ownership Group for~~Company’s chief operating officer.

In December 2017 and January 2018, options to purchase 400,000 shares of commons stock at an ~~aggregate 75~~exercise price of $0.025 were forfeited by the CEO and by an independent board member (200,000 shares forfeited by each individual).

In January 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77 and expiring between December 2020 and December 2022, as disclose in Note 9. Also during this month, the CEO and a board member each forfeited options to purchase 100,000 shares of common stock.

During the nine months ended September 30, 2018, a current board member exercised options to purchase 400,000 shares of common stock, and the former CFO of the Company exercised options to purchase 300,000 shares of common stock. These options were exercised at exercise prices ranging from $0.08 to $0.63 per share. During the same period ended September 30, 2017, as disclosed in Notes 8 and 9, options to purchase 4.5 million shares of common stock were exercised by the former CEO of the Company, who is a currently a board member, at an exercise price of $0.01 per share.

During the nine months ended September 30, 2018 and 2017, the Company issued 170,000 and 202,541 shares, respectively, of common stock for services rendered by the former CFO of the Company. Based on the market value of the common stock on the dates of the two issuances, the Company recorded non-cash losses of approximately $112,000 in 2018 and $31,000 in 2017.

At September 30, 2018 and December 31, 2017, the Company owed an aggregate of approximately $33,000 to the CEO and CFO.

The captionDue from Related Partiesin the Company’s financial statements is primarily comprised of ~~short term~~short-term loans to non-consolidated entities under common ownership.

The captionDue to Related Parties reflects short term loans from related parties and includes advances received from officers of the Company.

NOTE 912 –COMMITMENTS AND CONTINGENCIES

An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017.

The Company recorded an accrual of approximately $1,043,000 at ~~March 31,~~September 30, 2018 and December 31, 2017 for any amounts that may be owed under this agreement. However, the Company is ~~reviewing~~contesting the validity this ~~matter.~~agreement.

NOTE 1013 – SEGMENT REPORTING

In accordance with ASC 280, the following is information regarding the Company’s operating segments:

Three Months Ended March 31,
2018 2017
Revenues:
Online portal operations $ — $ 61
Cannabis operations 2,082,950 1,150,658
Consolidated revenues $ 2,082,950 $ 1,150,719

Depreciation:
Online portal operations $ — $ —
Cannabis operations 80,791 69,827
Depreciation and amortization $ 80,791 $ 69,827

Net income (loss):
Online portal operations $ (103 ) $ (138,023 )
Cannabis operations (1,831,806 ) 247,409
Net income (loss) $ (1,831,909 ) $ 109,386

Capital expenditures:
Online portal operations $ — $ —
Cannabis operations 1,294,858 1,806,655
Combined capital expenditures $ 1,294,858 $ 1,806,655

Assets:
Online portal operations $ 1,295 $ 4,576
Cannabis operations 33,936,779 10.845,183
Combined assets $ 33,938,074 $ 10,849,759

	Nine Months Ended September 30,
	2018			2017
Revenues:
Online portal operations	$	—		$	289
Cannabis related operations		8,411,858			4,487,184
Consolidated revenues	$	8,411,858		$	4,487,473

Depreciation:
Online portal operations	$	—		$	—
Cannabis related operations		445,504			263,624
Depreciation	$	445,504		$	263,624

Net income (loss):
Online portal operations	$	(207	)	$	(31,903	)
Cannabis related operations		(18,221,440	)		331,864
Net income (loss)	$	(18,221,647	)	$	300,161

Capital expenditures:
Online portal operations	$	—		$	—
Cannabis related operations		7,259,413			11,502,688
Combined capital expenditures	$	7,259,413		$	11,502,688

Assets:
Online portal operations	$	1,191		$	1,476
Cannabis related operations		57,132,308			21,370,942
Combined assets	$	57,133,499		$	21,372,418

NOTE 1114 – SUBSEQUENT EVENTS

Notes Receivable

In October and November 2018, the Company purchased an additional $23.25 million of GC Debentures, at which time the Company entered into a Subscription Agreement for Convertible Debentures (the “SA”) with GenCanna governing the aggregate GC Debentures purchased of $30 million. The SA maintains the provisions of the $6.75M of GC Debentures previously purchased as of September 30, 2018 and disclosed in Note 4. Additionally, among other provisions, the Company shall have the right to appoint one director to GenCanna’s board, and shall fund a $10 million employee bonus pool should GenCanna meet certain 2019 operating targets.

Pursuant to a Security and Pledge Agreement executed with GenCanna in November 2018, the Company was granted a senior security interest on certain assets of GenCanna equal in value to 100% or more of the principal and accrued interest on the GC Debentures until such time the GC Debentures are paid down, redeemed or converted. Additionally, the Company was granted certain other rights, pursuant to a Rights Agreement, including rights of inspection, financial information, and participation in future security offerings of GenCanna.

Conversion of the Company’s entire $30 million investment shall equate to at least a 33.3% ownership interest in GenCanna on a fully diluted basis.

~~Thefollowing transactions occurred subsequent~~Debt Issuance

In October and November 2018, pursuant to ~~March 31, 2018:~~the terms of a Securities Purchase Agreement (the “SPA”), the Company sold an aggregate of $10,000,000 convertible debentures bearing interest at the rate of 6% per annum that mature three years from issuance, with a 1% issue discount, resulting in net proceeds to the Company of $9,900,000 (the “$10M Debentures”).

The holder of the $10M Debentures (the “Holder”) shall have the right at any time to convert all or a portion of the $10M Debenture, along with accrued and unpaid interest, into the Company’s common stock at conversion prices equal to 80% of a calculated average, as determined in the $10M Debentures, of the daily volume-weighted price during the ten consecutive trading days preceding the date of conversion. Notwithstanding this conversion right, the Holder shall limit conversions in any given month to certain agreed-upon values based on the conversion price, and the Holder shall also be limited from beneficially owning more than 4.99% of the Company’s outstanding common stock (potentially further limiting the Holder’s conversion right).

The Company shall have the right to redeem all or a portion of the $10M Debentures, along with accrued and unpaid interest, at a 10% premium, provided however that the Company first provide advance written notice to the Holder of its intention to make a redemption, with the Holder allowed to affect one or more conversions of the $10M Debentures during such notice period.

Upon a change in control transaction, as defined in the $10M Debentures, the Holder may require the Company to redeem all or a portion of the $10M Debentures at a price equal to 110% of the principal amount of the $10M Debentures plus all accrued and unpaid interest thereon. So long as the $10M Debentures are outstanding, in the event the Company enters into a Variable Rate Transaction (“VRT”), as defined in the SPA, the Holder may cause the Company to revise the terms of the $10M Debentures to match the terms of the convertible security of such VRT. As part of issuance of the $10M Debenture, the Company issued three-year warrants to the Holder to purchase 324,675 shares of common stock at exercise prices of $3.50 and $5.50 per share (the “Warrants”).

Pursuant to the terms of a Registration Rights Agreement with the Holder, entered into concurrently with the SPA and the $10M Debentures, the Company agreed to provide the Holder with customary registration rights with respect to any potential shares issued pursuant to the terms of the SPA, the $10M Debentures, and the Warrants.

	-	Warrants to purchase 75,000 shares of common stock were exercised at an exercise price of $0.20 per share. Warrants to purchase 100,000 shares of common stock were issued at exercise prices of $0.90 and $1.75 per share, expiring 5 years from issuance.

	-	~~The Company issued 3,315,383 shares of common stock that were previously subscribed but not yet issued.~~

	-	~~The Company sold 240,513 shares of common stock at prices ranging from $0.65 to $0.90 per share, resulting in total proceeds of $198,000.~~

Acquisitions

In October 2018, the Company entered into a purchase agreement to acquire 100% of the ownership interests of KPG of Anna LLC and KPG of Harrisburg LLC, the Company’s two cannabis-licensed clients that operate medical marijuana dispensaries in the state of Illinois (both entities collectively, the “KPGs”), from the current ownership group of the KPGs (the “Sellers”). As part of this transaction, the Company will also acquire the Sellers’ ownership interests of Mari Holdings IL LLC, the Company’s subsidiary which owns the real estate in which the KPGs’ dispensaries are located (“Mari-IL”). The purchase price of 1,000,000 shares of the Company’s common stock shall be issued to the Sellers upon the closing of the transaction, which is dependent upon, among other closing conditions, the approval by the Illinois Department of Financial and Professional Regulation. After the transaction is effectuated, the KPGs and Mari-IL will be wholly-owned subsidiaries of the Company.

In October 2018, the Company’s cannabis-licensed client in Massachusetts, ARL Healthcare Inc. (“ARL”), filed a plan of entity conversion with the state to convert from a non-profit entity to a for-profit corporation. ARL holds three cannabis licenses from the state of Massachusetts for the cultivation, production and dispensing of cannabis. Upon approval of the conversion plan by the state, the Company shall be the sole shareholder of ARL, and shall elect its current COO to serve as ARL’s sole board member.

As of September 30, 2018, the Company had not yet received the legislative approval that is required for all ownership changes of cannabis licensees, and therefore the operations of the KPGs and ARL were not consolidated in the Company’s financial statements as of such date. The Company anticipates that approval for these transactions will be obtained, and those deals consummated, prior to the end of the current fiscal year, or in early 2019. When that occurs, the Company will consolidate the acquired entities in accordance with GAAP.

Equity Transactions

In October 2018, the Company (i) sold 4,999,242 shares of common stock at prices of $2.20 and $3.00 per share, resulting in total proceeds of $14,925,000, and (ii) issued three-year warrants to purchase 1,201,163 shares of common stock at exercise prices ranging from $3.50 to $5.50 per share.

In October 2018, warrants to purchase 222,775 shares of common stock were exercised at exercise prices ranging from $0.40 to $1.75 per share, and options to purchase 60,000 shares of common stock were exercised at an exercise price of $0.45 per share in a cashless transaction.

Item 2. Management’s Discussions and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

When used in this form 10-Q and in future filings by the Company with the Commission, the words or phrases such as “anticipate,” “believe,” “could,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on any such forward looking statements, each of which speak only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligation to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different. These factors include, but are not limited to, changes that may occur to general economic and business conditions; changes in current pricing levels that we can charge for our services or which we pay to our suppliers and business partners; changes in political, social and economic conditions in the jurisdictions in which we operate; changes to laws and regulations that pertain to our products and operations; and increased competition.

The following discussion should be read in conjunction with the unaudited financial statements and related notes which are included under Item 1.

We do not undertake to update our forward-looking statements or risk factors to reflect future events or circumstances.

Overview

General

We are aindustry experts in the development, operation, management ~~advisory company~~and optimization of cannabis cultivation, production, and dispensing facilities. Such facilities, located in multiple states, are leased to the Company’s clients in the emerging cannabis industry. ~~We provide our clients with industry leading expertise in the design, development, operation, funding, and optimization of medical cannabis cultivation, production, and dispensary facilities.~~ Our team acquires land and/or real estate for the purpose of developing state-of-the-art, regulatory-compliant legal cannabis facilities. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. These facilities are leased to the Company’s clients who are entities that have been awarded legal and medical marijuana licenses from multiple states. Along with this operational oversight, the Company provides its clients with legal, accounting, human resources, and other corporate and administrative services.

~~We currently have six active~~The Company also provides industry leading expertise and ~~fully operational facilities which are located~~consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states—two in Delaware, ~~(in~~two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, we have operating facilities located in the cities of Wilmington and ~~Lewes), Illinois (in~~Lewes in Delaware; the cities of Anna and ~~Harrisburg), Nevada (Clark county),~~Harrisburg in Illinois; Clark county in Nevada; Arundel county and ~~Maryland (in~~ the city of ~~Hagerstown). In addition, we currently have two facilities~~Hagerstown in ~~Massachusetts (in~~Maryland; and the cities of New Bedford, Norwood and ~~Middleborough) that are~~Middleborough in ~~the final stages~~Massachusetts. In total, we have developed in excess of ~~construction and are expected to be active and fully operational in 2018.~~300,000 square feet of seed-to-sale cannabis facilities.

In addition to our ~~medical~~ cannabis facilities, we are on the forefront of the development of precision-dosed, ~~cannabis medicine~~cannabis-infused products. Our proprietary branded products are comprised of Kalm Fusion™, designed for the treatment of specific medical conditions and related ~~symptoms. Our branded products, such as Kalm Fusion™ and~~symptoms, Betty’s Eddies™, the recently acquired ~~Betty’s Eddies™~~recreational-leaning brand of fruit chews, and Nature’s Heritage™, the newest member of the MariMed family of brands, consisting of organic products created from the finest seed lineages which we believe are ~~licensed~~“The best cannabis Mother Earth has to offer®”.

The Company also has exclusive sublicensing rights in ~~cannabis-legal~~certain states to distribute vaporizer pens developed by Lucid Mood™, as well as the clinically-tested medicinal cannabis strains developed in Israel by world-renowned Tikun Olam™. The Company continues to be committed to the licensing and distribution of branded cannabis products in states across the ~~country.~~country and beyond.

As of this filing, we have begun to execute on our strategy to evolve the Company into a direct cultivator, producer, and dispenser of cannabis and cannabis-related products, which we anticipate will significantly increase our revenues, profitability and overall operations. The following paragraphs highlight our efforts to date, which include the progress made on our recently announced strategic initiative to consolidate the operations of our cannabis-licensed clients and to acquire cannabis licensees in other states.

In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry.

In ~~May 2014,~~July 2018, the Company ~~through its subsidiary MariMed Advisors Inc. (“MMA”), acquired Sigal Consulting LLC (“Sigal”) from Sigal’s members, two of whom are now the CEO and CFO~~entered into a purchase agreement to acquire 100% of the ~~Company,~~ownership interests of AgriMed Industries of PA LLC, an entity that holds a license from the state of Pennsylvania for the cultivation of cannabis (“AgriMed”). AgriMed presently develops cannabis products that are wholesaled to medical marijuana dispensaries within the state. As required by state law, and in ~~exchange~~order to effectuate the transaction, the parties have applied for ~~(i) an aggregate amount~~legislative approval of the change in AgriMed’s ownership with respect to the Company’s acquisition, and are expecting receipt of written evidence thereof prior the end of the 2018 fiscal year.

In August 2018, the Company entered into an exclusive global licensing agreement for the production and distribution rights in all existing and future legal cannabis markets of a proprietary technology that prints precision-dosed dissolvable cannabis products. This technology facilitates the production of multiple combinations of cannabinoids, terpenes, and nutrients, while avoiding fillers commonly found in cannabis and nutraceutical products, into a paper-thin, low-calorie, fast-absorbing product that is delivered sublingually, transdermally, or by drinking when dissolved in liquid. The process also allows for the printing of any graphic, such as a bar code or website address, on each product. These products transport easily and discreetly in purses, pockets, and wallets, and are produced at higher levels of efficiency than the current methods within the cannabis industry.

In August 2018, the Company made a strategic investment in an entity that provides a customer relationship management and marketing platform specifically designed for companies in the cannabis industry (“Sprout”). The Company shall assist in the ongoing development and design of Sprout, and in marketing Sprout to companies within the cannabis industry.

During the period September to November 2018, pursuant to a subscription agreement, the Company purchased $30 million of subordinated secured convertible debentures (the “GC Debentures”) of GenCanna Global, Inc., a producer and distributor of agricultural hemp, cannabidiol (CBD) formulations, hemp genetics, and hemp products (“GenCanna”). The GC Debentures bear interest at a compounded rate of 9% per annum and mature three years from issuance. The GC Debentures are convertible into the common stock ~~equal~~of GenCanna, at the Company’s option, (i) upon the occurrence of a Liquidity Event, as defined in the GC Debentures, or (ii) after December 31, 2018, upon ten days prior written notice to ~~50%~~GenCanna. The conversion price shall be the lesser of a 20% discount to the price of the ~~Company’s outstanding shares~~Liquidity Event, or the price based on a defined post-money valuation of GenCanna. The Company was granted a senior security interest on certain assets of GenCanna equal in value to 100% or more of the principal and accrued interest on the ~~closing date; (ii) options~~GC Debentures. Additionally, the Company was granted certain other rights including rights of inspection, financial information, and participation in future security offerings of GenCanna. Conversion of the entire $30 million investment shall equate to at least a 33.3% ownership interest in GenCanna on a fully diluted basis.

In October 2018, the Company entered into a purchase ~~three million~~agreement to acquire 100% of the ownership interests of KPG of Anna LLC and KPG of Harrisburg LLC, the Company’s two cannabis-licensed clients that operate medical marijuana dispensaries in the state of Illinois (both entities collectively, the “KPGs”), from the current ownership group of the KPGs (the “Sellers”). As part of this transaction, the Company will also acquire the Sellers’ ownership interests of Mari Holdings IL LLC, the Company’s subsidiary which owns the real estate in which the KPGs’ dispensaries are located (“Mari-IL”). The purchase price of 1,000,000 shares of the Company’s common stock ~~exercisable over five years with exercise prices ranging from $0.15~~shall be issued to ~~$0.35,~~the Sellers upon the closing of the transaction, which is dependent upon, among other closing conditions, the approval by the Illinois Department of Financial and ~~(iii) a 49% ownership interest~~Professional Regulation. After the transaction is effectuated, the KPGs and Mari-IL will be wholly-owned subsidiaries of ~~MMA.~~

the Company.

In ~~June 2017, we acquired~~October 2018, the ~~remaining 49% interest~~Company’s cannabis-licensed client in ~~MMA in exchange~~Massachusetts, ARL Healthcare Inc. (“ARL”), filed a plan of entity conversion with the state to convert from a non-profit entity to a for-profit corporation. ARL holds three cannabis licenses from the state of Massachusetts for ~~75 million shares~~the cultivation, production and dispensing of ~~restricted common stock.~~

cannabis. Upon approval of the conversion plan by the state, the Company shall be the sole shareholder of ARL, and shall elect its current COO to serve as ARL’s sole board member. As of the date of this filing, the state has not finalized it review of the conversion, which is expected to be approved prior to the end of the 2018 fiscal year.

Revenues

Our revenues are currently comprised of the following primary categories:

Management – We receive fees for providing comprehensive oversight of our clients’ entire cannabis cultivation, production, and dispensary operations. Along with this oversight, we provide human resources, legal, accounting, sales, marketing, and reporting ~~services..~~

services.

Real Estate – Our state-of-the-art, regulatory-compliant legal cannabis facilities are leased to our cannabis-licensed clients over 20-year lease terms. We generate rental income from occupancy, tenant improvements, equipment rentals, and additional rental income based on the success of the cannabis licensees.

Licensing – We derive licensing revenue from the sale by the licensees of our branded precision-dosed cannabis-infused products, such as Kalm Fusion™ and Betty’s Eddies™, to legal dispensaries throughout the country.

Consulting – We assist third-parties in securing cannabis licenses, and provide advisory services in the areas of facility design and development, and cultivation and dispensing best practices

Supply Procurement – We have established large volume discounts with top national vendors of cultivation and production supplies and equipment, which we acquire and resell at competitive prices to our cannabis-licensed clients with a reasonable markup.

Expenses

We classify our expenses into three broad categories:

	●	cost of revenues, which includes the direct costs associated with the generation of our revenues, and depreciation expense on our properties and equipment;

	●	operating expenses, which include the sub-categories of personnel, marketing and promotion, and general and administrative; and

	●	non-operating expenses, which include the sub-categories of interest, non-cash ~~equity compensation,~~amortization of stock option and warrant issuances, and non-cash losses on debt settlements.

Liquidity and Capital Resources

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, we raised approximately ~~$1.5~~$16.9 million from the issuance of common stock, and ~~subscriptions on common stock. Additionally,~~$3.0 million from the issuance of a promissory note. In addition, capital of approximately ~~$525,000~~$2.0 million was ~~advanced~~extended to us for building improvements on our New Bedford, MA property by the terms of the secured lender.

In October 2018, the Company raised an additional $14,925,000 from the issuance of common stock.

In October and November 2018, pursuant to the terms of a Securities Purchase Agreement, the Company sold an aggregate of $10,000,000 convertible debentures bearing interest at the rate of 6% per annum that mature three years from issuance, with a 1% issue discount, resulting in net proceeds to the Company of $9,900,000.

These funds will be used to ~~fund Company operations,~~execute on our strategy to become a direct cultivator, producer, and dispenser of cannabis and cannabis-related products, continue the development of our facilities, and expand our branded licensing business. We continue to ~~pursue~~require and negotiate for additional sources of capital, ~~in 2018,~~ although there can be no assurance that any such capital will ~~become available.~~be available on terms that are acceptable to us.

RESULTS OF OPERATIONS

Three months ended ~~March 31,~~September30, 2018 compared to three months ended ~~March 31,~~September30, 2017

Revenues for the three months ended ~~March 31,~~September 30, 2018 ~~increased 81% to approximately $2,083,000, compared to $1,151,000~~nearly doubled from the same period a year ~~ago.~~ago, increasing 97.7% from approximately $1.7 million to approximately $3.4 million. This significant increase was primarily due to the ~~expanding operations~~growth of ~~our medical cannabis clients from whom we earn management fees,~~ rental income from our facilities in Maryland and Massachusetts which were fully developed and leased to tenants in late calendar 2017, and increased supply procurement ~~revenue (as explained~~services provided to the Company’s cannabis-licensee client in ~~the revenue section above).~~Marylandin 2018. For the three months ended ~~March 31,~~September30, 2018, the revenue generated by these ~~clients’ revenues~~clients increased 47.7% to approximately ~~$3.8~~$4.9 million from ~~$2.3~~approximately $3.3 million for the same period in 2017.

Cost of revenues increased tofrom approximately ~~$889,000~~$548,000 for the three months ended ~~March 31, 2018 from~~September 30, 2017 to approximately ~~$471,000~~$1,522,000 for the three months ended ~~March 31, 2017, attributable~~September 30, 2018. The increase was due a one-time payment of $250,000 to obtain the ~~growth in revenues over this period. As~~exclusive worldwide license of a ~~percentage of revenue, cost of revenues~~technology to produce and distribute cannabis products with exceedingly precise dosing at ~~March 31, 2018~~increased production economies, and ~~2017 were 43% and 41%, respectively. The marginal increase in this percentage is due to~~ a higher ~~component~~level of ~~revenues being comprised of~~cost associated with supply procurement ~~fees, which is lower-margin revenue compared~~from year to ~~our other revenue categories.~~year. Accordingly, gross profit as a percentage of revenue decreased ~~slightly~~ from ~~59%~~68.0% for the three months ended ~~March 31,~~September 30, 2017 to ~~57%~~55.1% for the three months ended ~~March 31,~~September 30, 2018. ~~Going forward, higher-margin consulting, management, real estate and licensing revenues are expected to comprise larger portions of total revenues.~~

Personnel expense increased to approximately ~~$185,000~~$352,000 for the three months ended ~~March 31,~~September 30, 2018 from ~~$168,000~~approximately $270,000 for the same period a year ago. Despite the increase in amount, which was the result of hiring additional staff to support the higher level of revenues, this expense decreased as a percentage of revenues to 10.4% in 2018 from ~~15%~~15.7% in ~~2017 to 9% in 2018.~~2017.

Marketing and promotion costs ~~decreased~~increased slightly to approximately ~~$52,000~~$37,000 for the three months ended ~~March 31,~~September 30, 2018 from approximately ~~$69,000~~$29,000 for the same period a year ago. ~~This decrease is due~~As a percentage of revenue, these costs decreased to 1.1% from 1.7% for the ~~lower need to use third-parties to promote the Company within the medical cannabis industry.~~three months ended September 30, 2018 and 2017, respectively.

General and administrative costs increased to approximately ~~$706,000~~to $619,000 for the three months ended ~~March 31,~~September 30, 2018 from approximately ~~$214,000~~$581,000 for the same period a year ago. Despite the dollar increase, these costs decreased as a percentage of revenues to 18.3% from 33.9%, demonstrating our successful leveraging of our infrastructure to generate higher levels of profitability.

As a result of the above, operating income more than doubled from approximately $287,000 or 16.7% of revenue for the three months ended September 30, 2017, to approximately $861,000 or 25.4% of revenue for the three months ended September 30, 2018.

Non-operating expenses of approximately $11.0 million for the three months ended September 30, 2018 were primarily comprised of (i) interest expense on our mortgages and notes payable of approximately $478,000, offset by interest income on our note receivable of approximately $23,000, (ii) non-cash amortization of stock option and warrant issuances of approximately $8.1 million arising from the issuance of stock options and warrants, and (iii) non-cash losses on the settlement of debt via the issuance of common stock of approximately $2.4 million. The two non-cash items, required by generally accepted accounting principles, had no effect on the operating earnings or liquidity of the Company. These non-cash items gave rise to the large year-over-year increase. For the same period in 2017, non-operating expenses approximated $601,000 and were comprised of (a) net interest expense of approximately $90,000, and (b) non-cash amortization of stock option and warrant issuances, and debt settlement losses of approximately $738,000, offset by a gain of approximately $227,000 from the write-off of deferred revenue.

As a result of the foregoing, we realized a net loss of approximately $314,000 for the three months ended September 30, 2017, compared with a net loss of approximately $10.1 million in 2018. The net losses were due to the previously explained non-cash items which had no impact on the Company’s operating income or cash flow. Excluding these non-cash items, net income for the three months ended September 30, 2017 and 2018 was approximately $197,000 and $406,000, respectively.

Nine months endedSeptember30, 2018 compared to nine months endedSeptember30, 2017

Revenues for the nine months endedSeptember30, 2018 increased 87.5% to approximately $8.4 million, compared with $4.5 million from the same period a year ago. This significant increase was primarily due to the growth of (i) rental income from our facilities in Maryland and Massachusetts which were fully developed and leased to tenants in late calendar 2017, (ii) supply procurement services provide to additional cannabis licensees in 2018, and (iii) management fees and additional rental revenue which we earn based on a percentage of revenue generated by our cannabis-licensed clients. For the nine months endedSeptember30, 2018, the revenue generated by these clients increased 56.6% to approximately $13.1 million from approximately $8.4 million for the same period in 2017.

Cost of revenues increased to approximately $3.3 million for the nine months ended September 30, 2018 from approximately $1.5 million for the nine months ended September 30, 2017. As a percentage of revenue, cost of revenues for the nine months ended September 30, 2018 increased to 39.5% from 33.2% for the same period in 2017. This increase was attributable to a higher level of cost associated with supply procurement and licensed products from year to year, as well as a one-time payment of $250,000 to obtain the exclusive worldwide license of a technology to produce and distribute cannabis products with exceedingly precise dosing at increased production economies. Accordingly, gross profit as a percentage of revenue for the nine months ended September 30, 2018 decreased to 60.5% from 66.8% for the same period in 2017.

Personnel expense increased to approximately $822,000 for the nine months ended September 30, 2018 from $575,000 for the same period a year ago. Despite the increase in amount, which was the result of hiring additional staff to support the higher level of revenues, this expense decreased as a percentage of revenues to 9.8% in 2018 from 12.8% in 2017.

Marketing and promotion costs increased to approximately $167,000 for the nine months ended September 30, 2018 from approximately $144,000 for the same period a year ago. These costs decreased relative to the growth in revenues from year to year, representing 2.0% and 3.2% of revenues in 2018 and 2017, respectively.

General and administrative costs increased to approximately $2,141,000 for the nine months ended September 30, 2018 from approximately $1,164,000 for the same period a year ago. Year over year, these costs remained at a steady 25% of revenues. This increase is predominantly due to the utilities, real estate taxes, security, and other cost associated with operating an increased number of active facilities, and is commensurate with the growth of revenues and the overall business.

As a result of the above, operating income increased 75.4% from approximately $1.1 million during the nine months ended September 30, 2017, to approximately $2.0 million during the nine months ended September 30, 2018.

Non-operating expenses of approximately $20.2 million for the nine months ended September 30, 2018 were primarily comprised of (i) interest expense on our mortgages and notes payable of approximately $1,081,000, offset by interest income on our note receivable of approximately $62,000, (ii) non-cash ~~equity compensation arising from the issuing~~amortization of stock ~~options~~option and ~~warrants,~~warrant issuances of approximately $15.0 million, and (iii) non-cash losses on the settlement of debt via the issuance of common stock ~~and subscriptions on common stock.~~of approximately $4.2 million. The two non-cash items, ~~are~~ required by generally accepted accounting principles, ~~but have~~had no effect on the operating earnings or liquidity of the ~~Company. These non-cash items are one-time in nature~~Company, and ~~are~~ the cause for the large year-over-year variation in non-operating expenses. For the same period in 2017, non-operating expenses approximated $816,000 and were comprised of (a) net interest expense of approximately $268,000, and (b) non-cash amortization of stock option and warrant issuances, and debt settlements of approximately $776,000, offset by a gain of approximately $227,000 from the write-off of deferred revenue.

As a result of the foregoing, we incurred a net loss of approximately ~~$1,832,000~~$18.2 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2018, compared to net income of approximately ~~$109,000~~$300,000 from the same period a year ago. The loss in the current period is due to the previously explained large non-cash expenses which had no impact on the Company’s operating income or cash flow. Excluding these non-cash items, net income for the nine months ended September 30, 2018 was approximately $936,000.

Subsequent Events

Notes Receivable

In October and November 2018, the Company purchased an additional $23.25 million of GC Debentures, at which time the Company entered into a Subscription Agreement for Convertible Debentures (the “SA”) with GenCanna governing the aggregate GC Debentures purchased of $30 million. The SA maintains the provisions of the $6.75M of GC Debentures previously purchased as of September 30, 2018. Additionally, among other provisions, the Company shall have the right to appoint one director to GenCanna’s board, and shall fund a $10 million employee bonus pool should GenCanna meet certain 2019 operating targets.

Conversion of the Company’s entire $30 million investment shall equate to at least a 33.3% ownership interest in GenCanna on a fully diluted basis.

Debt Issuance

In October and November 2018, pursuant to the terms of a Securities Purchase Agreement (the “SPA”), the Company sold an aggregate of $10,000,000 convertible debentures bearing interest at the rate of 6% per annum that mature three years from issuance, with a 1% issue discount, resulting in net proceeds to the Company of $9,900,000 (the “$10M Debentures”).

Upon a change in control transaction, as defined in the $10M Debentures, the Holder may require the Company to redeem all or a portion of the $10M Debentures at a price equal to 110% of the principal amount of the $10M Debentures plus all accrued and unpaid interest thereon. So long as the $10M Debentures are outstanding, in the event the Company enters into a Variable Rate Transaction (“VRT”), as defined in the SPA the Holder may cause the Company to revise the terms of the $10M Debentures to match the terms of the convertible security of such VRT. As part of issuance of the $10M Debenture, the Company issued three-year warrants to the Holder to purchase 324,675 shares of common stock at exercise prices of $3.50 and $5.50 per share (the “Warrants”).

~~Subsequent Events~~Acquisitions

~~Thefollowing transactions occurred subsequent~~In October 2018, the Company entered into a purchase agreement to ~~March 31, 2018:~~acquire 100% of the ownership interests of KPG of Anna LLC and KPG of Harrisburg LLC, the Company’s two cannabis-licensed clients that operate medical marijuana dispensaries in the state of Illinois (both entities collectively, the “KPGs”), from the current ownership group of the KPGs (the “Sellers”). As part of this transaction, the Company will also acquire the Sellers’ ownership interests of Mari Holdings IL LLC, the Company’s subsidiary which owns the real estate in which the KPGs’ dispensaries are located (“Mari-IL”). The purchase price of 1,000,000 shares of the Company’s common stock shall be issued to the Sellers upon the closing of the transaction, which is dependent upon, among other closing conditions, the approval by the Illinois Department of Financial and Professional Regulation. After the transaction is effectuated, the KPGs and Mari-IL will be a wholly-owned subsidiary of the Company.

	-	Warrants to purchase 75,000 shares of common stock were exercised at an exercise price of $0.20 per share. Warrants to purchase 100,000 shares of common stock were issued at exercise prices of $0.90 and $1.75 per share, expiring 5 years from issuance.

	-	~~The Company issued 3,315,383 shares of common stock that were previously subscribed but not yet issued.~~

	-	~~The Company sold 240,513 shares of common stock at prices ranging from $0.65 to $0.90 per share, resulting in total proceeds of $198,000.~~

Equity Transactions

Item 4. Controls and Procedures

As of ~~March 31,~~September 30, 2018, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of ~~March 31,~~September 30, 2018. The above statement notwithstanding, you are cautioned that no system is foolproof.

Changes in Internal Control Over Financial Reporting

During the quarter covered by this report there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s reports in this quarterly report.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

Item 1A. Risk Factors

We are not obligated to disclose our risk factors in this report, however, limited information regarding our risk factors appears in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” under the caption “Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q. and in “Item 1A. RISK FACTORS” of our Annual Report on Form 10-K. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the ~~three~~nine months ended ~~March 31,~~September 30, 2018, the Company ~~issued 1,200,000~~sold 10,111,578 shares of ~~common stock and subscriptions on 1,319,214 shares of~~restricted common stock at prices ranging from $0.50 to ~~$0.95~~$1.37 per share, resulting in total proceeds of ~~$1,475,000.~~

~~During~~approximately $8.5 million. These funds will be used to fund Company operations, continue the ~~three months ended March 31, 2018, the Company issued 295,000 shares~~development of ~~common stock~~our facilities, and ~~subscriptions on 738,462 shares of common stock to settle outstanding obligations.~~expand our branded licensing business.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

~~None.~~

On November 8, 2018, we purchased an additional $17.25 million of subordinated secured convertible debentures (the “GC Debentures”) of GenCanna Global, Inc., a world leader in the production and distribution of agricultural hemp, cannabidiol (CBD) formulations, hemp genetics, and hemp products (“GenCanna”). As a result of such purchase, our investment in the GC Debentures aggregated $30 million.

The GC Debentures bear interest at a compounded rate of 9% per annum and mature three years from issuance. We have been granted (i) a senior security interest on certain assets of GenCanna equal in value to 100% or more of the principal and accrued interest on the GC Debentures, and (ii) certain other rights including the right to appoint a member to GenCanna’s board of directors, rights of inspection and the right to participate in future offerings of securities by GenCanna.

The GC Debentures are convertible into the common stock of GenCanna, at our option, (i) upon the occurrence of a Liquidity Event, as defined in the GC Debentures, or (ii) after December 31, 2018, upon ten days prior written notice to GenCanna. The conversion price is equal to the lesser of a 20% discount to the price of the Liquidity Event, or the price based on a defined post-money valuation of GenCanna. If a Liquidity Event does not occur on or before June 30, 2020, the Company shall have the option to be redeemed in cash for the principal amount of the GC Debenture plus all accrued and unpaid interest thereon.

Conversion of the entire $30 million of GC Debentures would equate to at least a 33.3% interest in GenCanna on a fully diluted basis.

Item 6. Exhibits

3.1		Certificate of Incorporation of the Registrant. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.

3.1.1		Amended Certificate of Incorporation of the Registrant. Incorporated by reference from Annual Report on Form 10-K filed on April 17, 2017.

3.2		Bylaws – Restated as Amended. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.

10.1		Subscription Agreement for Convertible Debentures between the Registrant and GenCanna Global, Inc. dated November 7, 2018

10.2		Form of Subordinated Secured Convertible Debenture of GenCanna Global, Inc.

10.3		Rights Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc. and others

10.4		Security and Pledge Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc.

31.1		Certification of Chief Executive Officer

31.2		Certification of Chief Financial Officer

32.1		Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101.INS* XBRL		Instance Document

101.SCH* XBRL		Taxonomy Extension Schema

101.CAL* XBRL		Taxonomy Extension Calculation Linkbase

101.DEF* XBRL		Taxonomy Extension Definition Linkbase

101.LAB* XBRL		Taxonomy Extension Label Linkbase

101.PRE* XBRL		Taxonomy Extension Presentation Linkbase

1924

SIGNATURES

In accordance with the requirements of the Exchange Act, the Registrant caused this Report to be signed on its behalf by the undersigned thereto duly authorized.

Date: ~~May 15,~~November 14, 2018

~~MARIMED INC.~~

MARIMED INC.

By:	/s/ Robert Fireman
	Robert Fireman
	President and Chief Executive Officer

By:	/s/ Jon R. Levine
	Jon R. Levine
	Chief Financial Officer

2025

INDEX TO EXHIBITS

Exhibit No.		Description

3.1		Certificate of Incorporation of the Registrant. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.

3.1.1		Amended Certificate of Incorporation of the Registrant. Incorporated by reference from Annual Report on Form 10-K filed on April 17, 2017.

3.2		Bylaws – Restated as Amended. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.

10.1		Subscription Agreement for Convertible Debentures between the Registrant and GenCanna Global, Inc. dated November 7, 2018

10.2		Form of Subordinated Secured Convertible Debenture of GenCanna Global, Inc.

10.3		Rights Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc. and others

10.4		Security and Pledge Agreement dated November 7, 2018 between the Registrant and GenCanna Global, Inc.

31.1		Certification of Chief Executive Officer

31.2		Certification of Chief Financial Officer

32.1		Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101.INS* XBRL		Instance Document

101.SCH* XBRL		Taxonomy Extension Schema

101.CAL* XBRL		Taxonomy Extension Calculation Linkbase

101.DEF* XBRL		Taxonomy Extension Definition Linkbase

101.LAB* XBRL		Taxonomy Extension Label Linkbase

101.PRE* XBRL		Taxonomy Extension Presentation Linkbase

	March 31, 2018			December 31, 2017
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	409,593		$	1,290,231
Accounts receivable, net		2,122,044			1,453,484
Deferred rents receivable		724,827			610,789
Due from third parties		1,844,050			1,196,918
Due from related parties		134,781			134,781
Note receivable, current portion		46,879			45,444
Other current assets		376,459			357,019
Total current assets		5,658,633			5,088,666

Property and equipment, net		27,168,997			25,954,931
Note receivable, long-term portion		566,999			578,831
Other assets		543,445			579,587
Total assets	$	33,938,074		$	32,202,015

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,721,103		$	2,831,658
Accrued expenses		1,445,403			1,405,336
Due to related parties		200,996			400,996
Mortgages payable, current portion		119,668			118,556
Common stock subscriptions		3,236,001			-
Notes payable		9,215,249			10,665,899
Total current liabilities		16,938,420			15,422,445

Mortgages payable, long-term portion		6,026,376			5,532,397
Notes payable		-			-
Other liabilities		240,013			240,013
Total liabilities		23,204,809			21,194,855

Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2018 and December 31, 2017; no shares issued or outstanding at March 31, 2018 and December 31, 2017		-			-
Series A preferred stock subscribed but not issued; zero and 500,000 shares at March 31, 2018 and December 31, 2017, respectively		-			500
Common stock, $0.001 par value; 500,000,000 shares authorized at March 31, 2018 and December 31, 2017; 179,795,933 and 176,940,331 shares issued at March 31, 2018 and December 31, 2017, respectively; 179,705,933 and 176,850,331 shares outstanding at March 31, 2018 and December 31, 2017, respectively		179,796			176,940
Common stock subscribed but not issued; 1,000,000 shares at March 31, 2018 and December 31, 2017		370,000			370,000
Subscriptions receivable		(25,000	)		(25,000	)
Common stock warrants		2,382,726			2,176,379
Treasury stock, at cost; 90,000 shares at March 31, 2018 and December 31, 2017		(45,000	)		(45,000	)
Additional paid-in capital		21,563,178			20,149,591
Accumulated deficit		(13,866,883	)		(11,971,740	)
Noncontrolling interests		174,448			175,490
Total stockholders’ equity		10,733,265			11,007,160
Total liabilities and stockholders’ equity	$	33,938,074		$	32,202,015